Asparaginase市场：现状分析与预测（2022-2028）

Asparaginase Market: Current Analysis and Forecast (2022-2028)

出版日期: 2023年07月31日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

由于製药行业研发的扩大以及 FDA 对Asparaginase药物的批准增加，Asparaginase市场预计将稳定增长约 16.4%。根据美国食品药品监督管理局（FDA）报告的数据，2021年6月30日，FDA批准了Asparaginase新剂型Erwinia chrysanthemi（重组）-rywn（Rylaze）。 Rylaze 被批准作为儿童和成人治疗策略的一部分，用于治疗类似于 ALL 的侵袭性血癌。此外，2022 年 11 月，Jazz Pharmaceutical PLC 宣布 Ryleyse FDA-Seq（Asparaginase Erwinia 宣布美国 FDA 批准用于肌内（IM）施用 chrysanthemi（重组）-rywn 的补充生物製剂许可申请（SBLA））。因此，製药行业的扩张、研发的增加以及 FDA 的批准可能会对预测期内的市场增长产生积极影响。

按类型，市场分为大肠桿菌、菊欧文氏菌和聚乙二醇化产品。在2021年的市场中，大肠桿菌类别占据压倒性份额。这主要是由于癌症治疗中对大肠桿菌Asparaginase的需求增加。根据纽约罗彻斯特大学对三种Asparaginase製剂的药代动力学比较研究，大肠桿菌Asparaginase的出现是由于癌症治疗中对大肠桿菌Asparaginase的需求增加。大肠桿菌Asparaginase的生物半衰期（1.44 天）比大肠桿菌（1.44 天）和 PEG Asparaginase的生物半衰期短得多（0.65 天）。因此，大肠桿菌被广泛用于治疗ALL，并且是治疗癌症的首选药物。因此，癌症治疗中对大肠桿菌的需求不断增加预计将在预测期内积极推动Asparaginase市场。

根据应用，市场分为急性淋巴细胞白血病、急性髓细胞白血病和其他（霍奇金病）。急性淋巴细胞白血病领域预计在预测期内将以高复合年增长率增长。这是由于它越来越多地用于治疗淋巴增殖性疾病和淋巴瘤。根据健康指标与评估研究所的数据，2019 年全球报告了约 153,000 例急性淋巴细胞白血病新病例。这些是预计在预测期内推动市场的因素。

根据最终用途，市场分为医院、诊所、零售药店和在线药店。 2021年，医院占据压倒性的市场份额。由于医疗基础设施的快速发展，预计预测期内对Asparaginase的需求将增加，研究活动将增加，导致主要市场参与者的研发投资相应增加。例如，2019 年，芝加哥百万大学获得了约 100 万美元的天冬□胺资助，用于开发毒性较小的化疗药物治疗 ALL。

为了更好地了解Asparaginase市场的采用情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、西班牙、意大利、欧洲其他地区）、亚太地区（中国、日本、印度等亚太地区）以及世界其他地区。由于 ALL 和 LBL 患病率上升等因素，预计亚太地区在预测期内将以显着的复合年增长率增长。此外，该地区研发活动的增加预计将积极推动市场增长。例如，在印度，2021年3月，印度理工学院（IIT）印多尔开发了一种新蛋白质，这是一种治疗淋巴母细胞淋巴瘤的工程方法，具有急性副作用。

Asparaginase is a drug that is used in the treatment of acute lymphatic leukemia (ALL), lymphoblastic lymphoma (LBL), and certain types of blood cancers. It works by breaking down the amino acid asparagine and may block the growth of the tumour cells that requires asparagine to grow. It is an enzyme obtained chemically from the bacterium Escherichia coli (E.coli), Erwinia chrysanthemi, Pegylated, fungi, algae, and many more. Research and development studies are being carried out for the expansion of its application area in various fields such as nanomedicine, biomedical engineering, and many more.

The Asparaginase Market is expected to grow at a steady rate of around 16.4% owing to the expansion of pharmaceutical industry R&D and an increase in FDA approvals for asparaginase drugs. According to the data from the Food Drug Administration (FDA) report, on June 30, 2021, the FDA approved Erwinia chrysanthemi (recombinant)-rywn (Rylaze) a new form of asparaginase. Rylaze was approved as a part of the treatment regime in children and adults for the treatment of aggressive blood cancer that resembles ALL. Additionally, in November 2022, Jazz Pharmaceutical plc announced the USFDA approval for supplementary biologics license application (SBLA) to the intramuscular (IM) dosing for Rylaze FDA seeking (Asparaginase Erwinia chrysanthemi (recombinant)-rywn, for use as a component of a multi-agent chemotherapeutic regimen for the treatment of ALL and LBL in adult and pediatric patients. Thus, with expansion in the pharmaceutical industry, R&D, and increased FDA approvals, there will be a positive impact on market growth during the forecast period.

Based on Type, the market is segmented into Escherichia coli (E.coli), Erwinia chrysanthemi, and Pegylated. E.coli category held the dominant share in the market in 2021. This is mainly due to the increase in demand for E.Coli asparaginase in cancer treatment According to the study on Comparative pharmacokinetic studies of three asparaginase preparations conducted by the University of Rochester, New York. Erwinia chrysanthemi asparaginase has a much shorter biological half-life (0.65 days) than E.coli (1.44 days) or PEG asparaginase. Hence E.coli is widely used in the treatment of ALL and is the preferred drug of choice for the treatment of cancer. Thus the increased demand for E.coli for cancer treatment is anticipated to drive the market for asparaginase positively during the forecast period.

Based on Application, the market is segmented into acute lymphoblastic leukemia, acute myeloid leukemia, and Other (Hodgkin's disease). The acute lymphoblastic leukemia segment is expected to grow with a high CAGR during the forecast period. this is attributed to its increase use in the treatment of lymphoproliferative disorders and lymphoma. According to the Institute of Health Metrics and Evaluation, in 2019 about 153,000 new cases of acute lymphoblastic leukemia were reported globally. These are the elements that are anticipated to fuel the market during the forecast period.

Based on End-use, the market is segmented into hospitals, clinics, retail pharmacy and online pharmacy. Hospitals held the dominant share of the market in 2021. The rapidly growing health infrastructure is expected to increase the demand for asparaginase during the forecasting period, leading to increase research activities, along with this rising investment in research and development by the key market players. For instance, in 2019 University of Millions Chicago, secured funding of about USD 1 million for aspargine for the development of less toxic chemotherapy use in the treatment of ALL.

For a better understanding of the market adoption of asparaginase, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia Pacific is anticipated to grow with a significant CAGR during the forecast period, owing to factors, including the rising prevalence of ALL and LBL across the region. Furthermore, the increase in research and development activity in the region is anticipated to boost market growth positively. For instance, in India, in March 2021, the Indian Institute of Technology (IIT) Indore developed a new protein, an engineering approach, to treat lymphoblastic lymphoma with an acute side effect.

Some of the major players operating in the market include: Jazz Pharmaceuticals plc, Servier Pharmaceutical LLC, medac GmbH, Kyowa Kirin co, ltd., Taj Pharmaceuticals Limited., Creative Enzymes.,Bio Vendor R&D, Gennova Biopharmaceuticals Limited., Actiza Pharmaceutical Private Limited, Porton Biopharma

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Asparaginase Market
2.2. Research Methodology of the Asparaginase Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ASPARAGINASE MARKET COVID-19 IMPACT

6 GLOBAL ASPARAGINASE MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY PRODUCT

7.1. Escherichia coli
7.2. Euinia crysanthemi
7.3. Pegylated

8 MARKET INSIGHT BY APPLICATION

8.1. Acute lymphoblastic leukimia
8.2. Acute myleoblastic leukimia
8.3 Other (Hodgkin's disease)

9 MARKET INSIGHTS BY END-USERS

9.1 Hospitals

Clinics

Retail Pharmacy

Online Pharmacy

10 MARKET INSIGHTS BY REGION

10.1. North America Asparaginase Market
- 10.1.1. U.S.
- 10.1.2. Canada
- 10.1.3. Rest of North America
10.2. Europe Asparaginase Market
- 10.2.1. Germany
- 10.2.2. UK
- 10.2.3 Italy
- 10.2.4. France
- 10.2.8. Rest of Europe

Asia-Pacific Asparaginase Market